Grace Therapeutics (GRCE) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 46.4% versus a loss of 61.6%. Over five years, GRCE leads with a -79.3% price change compared with -95.9% for PLRX. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $36.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRCE | PLRX |
|---|---|---|
| Share price | $1.71 | $0.5951 |
| Market cap | $35.97M | $36.89M |
| 1-day change | -0.58% | -4.02% |
| YTD return | -50.58% | -51.22% |
| 1-year return | -46.39% | -61.61% |
| 5-year return | -79.35% | -95.89% |
| EPS (TTM) | $-1.16 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-7.79M | $-149.34M |
| 52-week high | $5.18 | $1.67 |
| 52-week low | $1.64 | $0.5719 |
| Distance from 52-week high | -66.99% | -64.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +243.27% | +236.08% |
| Average volume | 119.27K | 408.93K |
| Shares outstanding | 21.04M | 61.99M |
| Employees | 5 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed PLRX by 15.2 percentage points over the past year.
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
GRCE vs PLRX FAQ
Which is bigger, Grace Therapeutics or Pliant Therapeutics?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $35.97M for Grace Therapeutics (GRCE).
Which stock has performed better over the past year, GRCE or PLRX?
GRCE returned -46.39% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.
Are Grace Therapeutics and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.